

# Contents

Contributors

*xi*

Preface

*xv*

## 1. Vasotocin and the origins of the vasopressin/oxytocin receptor gene family

1

Sally A. Mayasich and Benjamin L. Clarke

1. Introduction

2

2. Emergence of the second ligand and derivation of the oxytocin receptor

6

3. Evolution of the V2A receptor and cAMP signaling

16

4. Promoter region regulatory elements and evolution of expression

19

5. Conclusions and future directions

21

Acknowledgments

23

References

24

## 2. Oxytocin/vasopressin-like neuropeptide signaling in insects

29

Edin Muratspahić, Emilie Monjon, Leopold Duerrauer, Stephen M. Rogers,

Darron A. Cullen, Jozef Vanden Broeck, and Christian W. Gruber

1. Introduction

30

2. OT/VP-like signaling in beetles

32

3. OT/VP-like signaling in locusts

35

4. OT/VP-like signaling in ants

39

5. Mining of ligand and receptor genes in other insects

42

6. Possible applications of insect inotocin ligands in pharmacology

45

Acknowledgments

48

References

48

## 3. Amyloid-like aggregation of provasopressin

55

Martin Spiess, Nicole Beuret, Cristina Prescianotto Baschong,

and Jonas Rutishauser

1. Biosynthesis and secretion of vasopressin

56

2. Autosomal dominant neurohypophyseal diabetes insipidus (ADNDI) caused by amyloid-like provasopressin aggregation in the ER

60

3. Granule sorting by functional amyloid aggregation in the TGN

64

*vii*

|                                                                                                  |            |
|--------------------------------------------------------------------------------------------------|------------|
| 4. Sequence elements mediating ER aggregation and granule sorting                                | 65         |
| 5. Provasopressin is a physiological substrate of ERAD                                           | 70         |
| Acknowledgments                                                                                  | 74         |
| References                                                                                       | 74         |
| <b>4. V2 vasopressin receptor mutations</b>                                                      | <b>79</b>  |
| Noriko Makita, Katsunori Manaka, Junichiro Sato, and Taroh Iiri                                  |            |
| 1. Short introduction: V2 receptor and its physiological role in the kidney                      | 80         |
| 2. <i>X-linked congenital nephrogenic diabetes insipidus (NDI)</i>                               | 80         |
| 3. Loss-of-function mutations of V2R that cause NDI                                              | 82         |
| 4. Gain-of-function mutations causing nephrogenic syndrome of inappropriate antidiuresis (NSIAD) | 92         |
| Acknowledgment                                                                                   | 94         |
| References                                                                                       | 94         |
| <b>5. Vasopressin inactivation: Role of insulin-regulated aminopeptidase</b>                     | <b>101</b> |
| Don T. Li, Estifanos N. Habtemichael, and Jonathan S. Bogan                                      |            |
| 1. Introduction: Antidiuretic activity is regulated enzymatically by vasopressin inactivation    | 102        |
| 2. Discovery and function of placental leucine aminopeptidase                                    | 104        |
| 3. Discovery and characterization of insulin regulated aminopeptidase (IRAP)                     | 106        |
| 4. TUG mediates coordinated regulation of water and glucose homeostasis                          | 113        |
| 5. Implications of vasopressin degradation: Copeptin and the metabolic syndrome                  | 115        |
| 6. Conclusion                                                                                    | 118        |
| Acknowledgments                                                                                  | 119        |
| References                                                                                       | 119        |
| <b>6. Molecular aspects of aquaporins</b>                                                        | <b>129</b> |
| Suchun Li, Chunling Li, and Weidong Wang                                                         |            |
| 1. Discovery of the first aquaporin                                                              | 130        |
| 2. Classification and isoforms of mammalian aquaporins                                           | 131        |
| 3. Structural characterization of mammalian aquaporins                                           | 137        |
| 4. Protein modification of AQP2                                                                  | 139        |
| 5. Molecular machinery of AQP2 trafficking                                                       | 150        |

|                                                                                                                                  |            |
|----------------------------------------------------------------------------------------------------------------------------------|------------|
| 6. AQP2 protein abundance by vasopressin and others                                                                              | 156        |
| 7. Pathophysiology of vasopressin-regulated AQP2                                                                                 | 159        |
| 8. Concluding remarks                                                                                                            | 163        |
| References                                                                                                                       | 163        |
| <b>7. The vasotocinergic system and its role in the regulation of stress in birds</b>                                            | <b>183</b> |
| Wayne J. Kuenzel, Seong W. Kang, and Alexander Jurkevich                                                                         |            |
| 1. Introduction                                                                                                                  | 184        |
| 2. Anatomy of the avian HPA axis, with emphasis on arginine vasotocin (AVT)                                                      | 185        |
| 3. Roles of AVT and CRH in regulating blood concentration of corticosterone in birds                                             | 194        |
| 4. Receptors associated with stress within the anterior pituitary and vasotocin antagonists specific for the avian V1a and V1bRs | 199        |
| 5. Conclusions and future directions                                                                                             | 207        |
| Acknowledgments                                                                                                                  | 207        |
| References                                                                                                                       | 208        |
| Further reading                                                                                                                  | 216        |
| <b>8. Vasopressin actions in the kidney renin angiotensin system and its role in hypertension and renal disease</b>              | <b>217</b> |
| Alexis A. Gonzalez, Nicolas Salinas-Parra, Flavia Cifuentes-Araneda, and Cristian Reyes-Martinez                                 |            |
| 1. Introduction                                                                                                                  | 218        |
| 2. Vasopressin and its receptors in the kidney                                                                                   | 219        |
| 3. Structural characterization of vasopressin receptors                                                                          | 221        |
| 4. Vasopressin actions in the kidney renin angiotensin system                                                                    | 226        |
| 5. Vasopressin in hypertension                                                                                                   | 227        |
| 6. Vasopressin and kidney disease                                                                                                | 228        |
| 7. Conclusions and future directions                                                                                             | 232        |
| References                                                                                                                       | 233        |
| <b>9. Vasopressin receptor subtypes and renal sodium transport</b>                                                               | <b>239</b> |
| Yu. V. Natochin and D.V. Golosova                                                                                                |            |
| 1. Phenomenology of vasopressin-induced natriuresis                                                                              | 240        |
| 2. Milestones of history                                                                                                         | 240        |
| 3. Vasopressin and receptors in the kidney                                                                                       | 241        |

|                                                                                                                                                |            |
|------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| 4. Renal sodium transport                                                                                                                      | 246        |
| 5. Natriuretic effect of vasopressin                                                                                                           | 249        |
| 6. Conclusions                                                                                                                                 | 252        |
| Acknowledgment                                                                                                                                 | 252        |
| References                                                                                                                                     | 253        |
| <b>10. Development and therapeutic potential of vasopressin synthetic analog [V<sup>4</sup>Q<sup>5</sup>]dDAVP as a novel anticancer agent</b> | <b>259</b> |
| Juan Garona, Marina Pifano, Giselle Ripoll, and Daniel F. Alonso                                                                               |            |
| 1. AVP analogs and cancer                                                                                                                      | 260        |
| 2. Design of novel AVP synthetic analogs as anticancer agents                                                                                  | 264        |
| 3. [V <sup>4</sup> Q <sup>5</sup> ]dDAVP as a second generation AVP analog with enhanced biological activity                                   | 269        |
| 4. Conclusions and future perspectives                                                                                                         | 280        |
| Acknowledgments                                                                                                                                | 282        |
| References                                                                                                                                     | 282        |
| <b>11. Vasopressin and vasopressin receptors in brain edema</b>                                                                                | <b>291</b> |
| Emil Zeynalov, Susan M. Jones, and J. Paul Elliott                                                                                             |            |
| 1. Vasopressin and vasopressin receptors                                                                                                       | 292        |
| 2. Brain edema                                                                                                                                 | 295        |
| 3. Water diffusion and vasopressin in brain edema                                                                                              | 296        |
| 4. Injury-induced brain edema and vasopressin                                                                                                  | 298        |
| 5. Subarachnoid hemorrhage (SAH)-induced brain edema and vasopressin                                                                           | 300        |
| 6. Kidneys, brain edema and vasopressin                                                                                                        | 301        |
| 7. Inflammation in brain edema and vasopressin                                                                                                 | 302        |
| 8. Liver disease-caused brain edema and vasopressin                                                                                            | 303        |
| 9. Summary                                                                                                                                     | 303        |
| Acknowledgments                                                                                                                                | 304        |
| References                                                                                                                                     | 304        |